Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotype-Guided P2Y<sub>12</sub>-Inhibitor De-Escalation Strategy in Acute Coronary Syndrome: Observational Evidence From the POPular-GUIDE PCI.

Circulation. Cardiovascular interventions·2026
Same author

Factors influencing pharmaceutical companies' decisions to pursue compassionate use programs in the EU: a qualitative study in The Netherlands.

Journal of pharmaceutical policy and practice·2026
Same author

Optimizing fluoropyrimidine therapy: Real-world impact of DPYD genotype-based dosing on severe toxicity rates.

British journal of clinical pharmacology·2025
Same author

Individual patient data meta-analysis of placebo-controlled trials of selective serotonin reuptake inhibitors submitted for regulatory approval in adult obsessive-compulsive disorder.

The British journal of psychiatry : the journal of mental science·2025
Same author

The impact of operational trial approaches on representativeness: Comparison of decentralized clinical trial participants, conventional trial participants, and patients in daily practice.

Drug discovery today·2025
Same author

Experiences with low-intervention clinical trials-the new category under the European Union Clinical Trials Regulation.

Clinical trials (London, England)·2025

Related Experiment Video

Updated: May 30, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

[Interaction between clopidogrel and proton pump inhibitors].

Ankie M Harmsze1, Anthonius de Boer, Henk Boot

  • 1St. Antonius Ziekenhuis, afd. Klinische Farmacie, Nieuwegein, the Netherlands. ankie.harmsze@cze.nl

Nederlands Tijdschrift Voor Geneeskunde
|July 21, 2011
PubMed
Summary

Proton pump inhibitors (PPIs) and clopidogrel drug interactions remain unclear. While omeprazole significantly reduces clopidogrel

Related Experiment Videos

Last Updated: May 30, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Area of Science:

  • Pharmacology
  • Drug Interactions
  • Cardiovascular Medicine

Background:

  • The interaction between proton pump inhibitors (PPIs) and clopidogrel is complex, with conflicting research findings.
  • Previous studies suggest potential impacts on platelet reactivity and clinical outcomes in patients taking clopidogrel.
  • Specific concerns exist regarding omeprazole's inhibition of CYP2C19, a key enzyme in clopidogrel metabolism.

Purpose of the Study:

  • To investigate the pharmacokinetic and pharmacodynamic interactions between various PPIs and clopidogrel.
  • To clarify the clinical significance of these drug interactions on patient outcomes.

Main Methods:

  • Review of existing literature, including randomized studies and pharmacokinetic analyses.
  • Comparison of the effects of different PPIs (omeprazole, pantoprazole, others) on clopidogrel's active metabolite exposure (AUC).
  • Assessment of PPIs' impact on platelet reactivity in clopidogrel-treated patients.

Main Results:

  • Omeprazole significantly reduced clopidogrel's active metabolite exposure by 50% and increased platelet reactivity.
  • Pantoprazole demonstrated a much weaker effect on clopidogrel pharmacokinetics and platelet reactivity.
  • Limited randomized studies exist for other PPIs, and conclusive evidence of clinically relevant interactions is lacking.

Conclusions:

  • Regulatory agencies advise against combining clopidogrel with omeprazole and esomeprazole due to CYP2C19 inhibition.
  • Despite concerns, current evidence does not conclusively establish a clinically significant interaction between all PPIs and clopidogrel.
  • Further randomized studies are needed to fully elucidate the interaction profiles of other PPIs with clopidogrel.